These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 3357201)
1. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells. Beckman RA; McFall PJ; Sikic BI; Smith SD J Natl Cancer Inst; 1988 May; 80(5):361-5. PubMed ID: 3357201 [TBL] [Abstract][Full Text] [Related]
2. Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro. Wassermann K; Zwelling LA; Mullins TD; Silberman LE; Andersson BS; Bakic M; Acton EM; Newman RA Cancer Res; 1986 Aug; 46(8):4041-6. PubMed ID: 3731072 [TBL] [Abstract][Full Text] [Related]
3. DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells. Scudder SA; Brown JM; Sikic BI J Natl Cancer Inst; 1988 Oct; 80(16):1294-8. PubMed ID: 3172256 [TBL] [Abstract][Full Text] [Related]
4. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Kühl JS; Durán GE; Chao NJ; Sikic BI Cancer Chemother Pharmacol; 1993; 33(1):10-6. PubMed ID: 8269583 [TBL] [Abstract][Full Text] [Related]
5. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Ghielmini M; Colli E; Bosshard G; Pennella G; Geroni C; Torri V; D'Incalci M; Cavalli F; Sessa C Cancer Chemother Pharmacol; 1998; 42(3):235-40. PubMed ID: 9685059 [TBL] [Abstract][Full Text] [Related]
6. Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells. Streeter DG; Johl JS; Gordon GR; Peters JH Cancer Chemother Pharmacol; 1986; 16(3):247-52. PubMed ID: 3457646 [TBL] [Abstract][Full Text] [Related]
7. Comparative cytotoxicities of various morpholinyl anthracyclines. Streeter DG; Taylor DL; Acton EM; Peters JH Cancer Chemother Pharmacol; 1985; 14(2):160-4. PubMed ID: 3971481 [TBL] [Abstract][Full Text] [Related]
8. Activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin in sensitive and resistant L5178Y lymphoblasts in vitro. Begleiter A; Leith MK; Johnston JB Cancer Res; 1994 Jan; 54(2):482-6. PubMed ID: 8275485 [TBL] [Abstract][Full Text] [Related]
9. Toxicity of 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin and doxorubicin in nude mice bearing human tumour xenografts. Ford CH; Richardson VJ; Pushpanathan C; Ali SK Anticancer Res; 1991; 11(5):1855-62. PubMed ID: 1768056 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow. Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708 [TBL] [Abstract][Full Text] [Related]
11. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Sikic BI; Ehsan MN; Harker WG; Friend NF; Brown BW; Newman RA; Hacker MP; Acton EM Science; 1985 Jun; 228(4707):1544-6. PubMed ID: 4012308 [TBL] [Abstract][Full Text] [Related]
12. Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. Lau DH; Lewis AD; Sikic BI J Natl Cancer Inst; 1989 Jul; 81(13):1034-8. PubMed ID: 2733045 [TBL] [Abstract][Full Text] [Related]
13. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Duran GE; Lau DH; Lewis AD; Kühl JS; Bämmler TK; Sikic BI Cancer Chemother Pharmacol; 1996; 38(3):210-6. PubMed ID: 8646794 [TBL] [Abstract][Full Text] [Related]
14. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Lau DH; Lewis AD; Ehsan MN; Sikic BI Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140 [TBL] [Abstract][Full Text] [Related]
15. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890 [TBL] [Abstract][Full Text] [Related]
16. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Lewis AD; Durán GE; Lau DH; Sikic BI Int J Radiat Oncol Biol Phys; 1992; 22(4):821-4. PubMed ID: 1544857 [TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Perez-Soler R; Ling YH; Zou Y; Priebe W Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162 [TBL] [Abstract][Full Text] [Related]
18. Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Seneviratne C; Goldenberg GJ Cancer Commun; 1989; 1(1):21-7. PubMed ID: 2640153 [TBL] [Abstract][Full Text] [Related]
19. Effect of morpholinyladriamycin analogs and adriamycin on the activities of DNA polymerase alpha and RNA polymerase II of chicken leukemia cells. Chuang LF; Chuang RY; Acton EM; Israel M; Yu M J Pharmacol Exp Ther; 1987 Jul; 242(1):372-7. PubMed ID: 2441029 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin. Salmon SE; Young L; Soehnlen B; Liu R J Clin Oncol; 1984 Apr; 2(4):282-6. PubMed ID: 6707716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]